Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

an antibody developed by NGM that could be used in NASH and type 2 diabetes. J&J handed back rights to Hanmi after efinopegdutide, a once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor ...

Its in-house pipeline in NASH is led by survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist partnered with Zealand Pharma that is also being developed as an obesity therapy and is ...

Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biotechnology company specializing in treating liver disease and obesity.